Table 4.
Surgical details
| Malnourished, n = 12 (40%) | Well-nourished, n = 18 (60%) | |
|---|---|---|
| Surgical procedure (n (%)) | ||
| PPPD/PRPD | 10 (83) | 14 (78) |
| Whipple | 1 (8) | 3 (17) |
| Distal pancreatectomy | 1 (8) | 1 (6) |
| Duration of surgery (minutes) | 393 (364–524) | 402 (291–436) |
| Estimated intraoperative blood loss (mL) | 375 (300–525) | 350 (250–500) |
| R-status (n (%)) | ||
| R0 | 5 (42) | 13 (72) |
| R1 | 7 (58) | 5 (28) |
| Postoperative stay | ||
| Length of ICU/MCU stay (days) | 1 (1–1.3) | 1 (0–1) |
| Length of hospital stay (days) | 9.5 (8.8–12.3) | 12 (7–18.8) |
| Complications | ||
| Clavien-Dindo ≥ 3 (n (%)) | 3 (25) | 4 (22) |
| Surgical reintervention (n (%)) | 3 (25) | 2 (11) |
| In-hospital mortality (n (%)) | - | - |
| Unplanned readmission < 30 days (n (%)) | - | 4 (22) |
| Histological diagnosis (n (%)) | ||
| Adenocarcinoma pancreas | 9 (75) | 5 (28) |
| Adenocarcinoma periampullary | 1 (8) | 6 (33) |
| IPMN | - | 3 (17) |
| Neuroendocrine tumor | 1 (8) | - |
| Other malignancy | - | 3 (17) |
| No malignancy | 1 (8) | 1 (6) |
| Adjuvant chemotherapy* | 7 (78) | 2 (40) |
Data are presented as a median (IQR) or a number (%)
IPMN intraductal papillary mucinous neoplasm. PPPD pylorus-preserving pancreatoduodenectomy, PRPD pylorus-resecting pancreatoduodenectomy, mL milliliters, ICU intensive care unit, MCU medium care unit
*In the Netherlands, adjuvant chemotherapy is solely prescribed to patients diagnosed with pancreatic adenocarcinoma. Hence, in this case, the percentage is in relation to adenocarcinoma pancreas